RPM Shows Promise for Safer, More Feasible Outpatient Bispecific Administration

EP: 1.Single Bispecific Strategy Shows Operational Efficiencies, Cost Savings in DLBCL and FL

EP: 2.Streamlining Lymphoma Care With Multi-Indication Bispecifics

EP: 3.Overcoming Operational Barriers to Bispecific Use in Community Oncology

EP: 4.Building Confidence in Community Bispecific Use Through Standardization

EP: 5.The Promise and Limits of Remote Patient Monitoring for Bispecific Antibodies

Now Viewing

EP: 6.RPM Shows Promise for Safer, More Feasible Outpatient Bispecific Administration

Tara M. Graff, DO, director of clinical research at Mission Cancer + Blood at the University of Iowa Health Care, spoke about the real-world application of remote patient monitoring (RPM) to support outpatient step-up dosing of bispecific antibodies, highlighting the balance between safety, patient selection, and operational feasibility. An abstract from ASH 2025 underscores the potential for RPM to enable outpatient administration while mitigating the need for prolonged inpatient monitoring, but Graff emphasized that the approach is not universally appropriate.

Patient selection is critical. Older, frail, or high-risk patients—particularly those unfamiliar with digital devices or lacking caregiver support—may not be ideal candidates for RPM, as proper use of monitoring equipment is essential to detect early signs of cytokine release syndrome CRS or immune effector cell–associated neurotoxicity syndrome ICANS. Graff described workflows in which patients and caregivers demonstrate competency with blood pressure cuffs, thermometers, and wearable devices before outpatient dosing. In contrast, younger, technologically savvy patients may benefit from RPM, enjoy the convenience of remaining at home, and respond quickly if alerts indicate changes in vital signs.

The discussion also highlighted implications for reimbursement and payer acceptance. RPM may make outpatient bispecific administration more financially feasible, particularly as payers increasingly scrutinize hospital-based delivery. Insurance coverage for RPM devices and monitoring programs can incentivize community practices to adopt outpatient models, while reducing hospital stays and associated costs. Graff emphasized that collaboration among pharmaceutical companies, payers, and clinical sites will be crucial to standardize RPM programs and ensure sustainable implementation.

The findings suggest that remote monitoring can expand outpatient bispecific delivery for select patient populations, improve convenience, and potentially reduce costs, but careful patient selection, human oversight, and supportive reimbursement frameworks remain essential for broader adoption.